跳转至内容
Merck
  • Dietary fat-associated osteoarthritic chondrocytes gain resistance to lipotoxicity through PKCK2/STAMP2/FSP27.

Dietary fat-associated osteoarthritic chondrocytes gain resistance to lipotoxicity through PKCK2/STAMP2/FSP27.

Bone research (2018-07-14)
Sung Won Lee, Jee Hyun Rho, Sang Yeob Lee, Won Tae Chung, Yoo Jin Oh, Jung Ha Kim, Seung Hee Yoo, Woo Young Kwon, Ju Yong Bae, Su Young Seo, Hokeun Sun, Hye Young Kim, Young Hyun Yoo
摘要

Free fatty acids (FFAs), which are elevated with metabolic syndrome, are considered the principal offender exerting lipotoxicity. Few previous studies have reported a causal relationship between FFAs and osteoarthritis pathogenesis. However, the molecular mechanism by which FFAs exert lipotoxicity and induce osteoarthritis remains largely unknown. We here observed that oleate at the usual clinical range does not exert lipotoxicity while oleate at high pathological ranges exerted lipotoxicity through apoptosis in articular chondrocytes. By investigating the differential effect of oleate at toxic and nontoxic concentrations, we revealed that lipid droplet (LD) accumulation confers articular chondrocytes, the resistance to lipotoxicity. Using high fat diet-induced osteoarthritis models and articular chondrocytes treated with oleate alone or oleate plus palmitate, we demonstrated that articular chondrocytes gain resistance to lipotoxicity through protein kinase casein kinase 2 (PKCK2)-six-transmembrane protein of prostate 2 (STAMP2)-and fat-specific protein 27 (FSP27)-mediated LD accumulation. We further observed that the exertion of FFAs-induced lipotoxicity was correlated with the increased concentration of cellular FFAs freed from LDs, whether FFAs are saturated or not. In conclusion, PKCK2/STAMP2/FSP27-mediated sequestration of FFAs in LD rescues osteoarthritic chondrocytes. PKCK2/STAMP2/FSP27 should be considered for interventions against metabolic OA.

材料
货号
品牌
产品描述

Sigma-Aldrich
JC-1, powder or solid (Crystals)
Sigma-Aldrich
5,6-二氯苯并咪唑 1-β-D-核苷
Sigma-Aldrich
MISSION® esiRNA, targeting human STEAP4
Sigma-Aldrich
MISSION® esiRNA, targeting human CIDEC